RE:ROUTE

A map of the alternative biomedical R&D landscape

Download the Mapping Download report

The current biomedical Research and Development (R&D) system serves profits over people. Despite the global crisis of high drug prices, R&D investments continue to focus on medicines that can be sold at high prices leaving much needed medicines undeveloped. This is failure of both the market and public policy.

In the last 15 years, various R&D initiatives have appeared in response to this failure. Some offer true alternative models of R&D driven by health needs, while others continue business as usual. UAEM’s RE:Route mapping provides a qualitative review of the alternative biomedical R&D initiatives around the world that are active or proposed. While this mapping covers a significant number of potential alternatives, it is evident that the need for fundamental change is as urgent as ever.

Re:Route aims to engage in a growing collaborative dialogue around the exploration of needs-driven and people-oriented biomedical R&D. This mapping is not intended to be fully comprehensive nor does it aim to make any judgements on the value of different initiatives. It draws attention to what is currently out there and provides a starting point for an ongoing and inclusive dialogue informed by facts. Please join us in taking this project forward!

Lack of access to essential medicines1

1
in
3

Globally

1
in
2

Sub-Saharan Africa

Approximately 1 in 3 people around the world lack access to essential medicines. In Sub-Saharan Africa, this rises to 1 in 2.

Reported cost per drug: Pharma Companies vs Alternative Initiatives2

$US 2.5B 2.0B 1.5B 1.0B 500m 0

$
0
B

Big Pharma

$
0
M

Alternative R&D Model

Some alternative R&D models have shown that it is possible to produce new drugs at a fraction of the cost that pharmaceutical companies claim to spend.

Major new antibiotics developed since 19853

30

  • 1985 1995
  • 2005
  • 2015

In the past 30 years, no major new antibiotics have been developed in response to increasing antimicrobial resistance.

Projected increase in non-communicable diseases (NCDs)4

0
%

Of all premature deaths caused by NCDs occur in low- and middle-income countries.

Many NCDs medicines are extremely high cost. eg: In Pakistan leukemia treatment costs US$ 20,000, 7 times the per capita income.

See Source

  1. p. 25. Working Group on Access to Essential Medicines. UN Millennium Project--Task Force on HIV/AIDS, Malaria, TB and Access to Essential Medicines. United Nations Development Programme. 2005.
  2. http://www.dndi.org/media-centre/press-releases/1711-dndi-rd-model.html
    2.6 billion price: http://www.nytimes.com/2014/11/19/upshot/calculating-the-real-costs-of-developing-a-new-drug.html?_r=0
  3. World Health Organization. “Antimicrobial Resistance: Global Report on Surveillance 2014.” http://www.who.int/drugresistance/publications/infographic-antimicrobial-resistance-20140430.pdf
  4. WHO discussion paper on Essential Medicines and Access to Basic health technologies for non-communicable diseases http://apps.who.int/medicinedocs/documents/s21671en/s21671en.pdf
Download the Mapping

Share the knowledge

We are taking part in a global network for a new approach to biomedical R&D that depends upon an open exchange of ideas and information. We invite you to join the conversation.

See Source

  1. 1 in 3: p. 25. Working Group on Access to Essential Medicines. UN Millennium Project--Task Force on HIV/AIDS, Malaria, TB and Access to Essential Medicines. United Nations Development Programme. 2005.
  2. 2%: Till, Brian. “How Drug Companies Keep Medicine Out of Reach,” The Atlantic. http://www.theatlantic.com/health/archive/2013/05/how-drug-companies-keep-medicine-out-of-reach/275853/ May 15, 2013.
  3. 7 days: World Health Organization. The World Medicines Situation 2011: Medicines Prices, Availability and Affordability. p.9 http://apps.who.int/medicinedocs/documents/s18065en/s18065en.pdf
  4. Delinkage: http://www.wto.org/english/tratop_e/trips_e/who_wipo_wto_e.htm
  5. 25,000: World Health Organization. Antibiotic resistance fact sheet. October 2015. http://ecdc.europa.eu/en/aboutus/organisation/Director%20Speeches/1201_Director_speech_EU_health_prize_journalists.pdf
  6. 11,315: Centers for Disease Control and Prevention. “2014 Ebola Outbreak in West Africa.” January 3, 2016. http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/
Back to top